Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Aratana Therapeutics to Report First Quarter 2019 Financial Results

Share:

LEAWOOD, Kan., April 22, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ:PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Wednesday, May 8 at 4:30 p.m. ET to discuss financial results from the first quarter ended March 31, 2019.

Aratana Therapeutics logo

Interested participants and investors may access the audio webcast or use the conference call dial-in:
     1 (866) 364-3820 (U.S.) 
     1 (855) 669-9657 (Canada
     1 (412) 902-4210 (International)

A replay of the first quarter 2019 results teleconference will be available the same day of the event and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10131046:
     1 (877) 344-7529 (U.S.) 
     1 (855) 669-9658 (Canada
     1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats. Our mission is to successfully develop and deliver best-in-class therapeutics, provide comprehensive service to veterinarians and serve as a collaborator of choice for human and animal health companies. We believe our therapeutics are highly differentiated, resolve recognizable needs in compelling markets and have therapeutic profiles superior to the standard of care. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
Rhonda Hellums
ir@aratana.com 
(913) 353-1026

For media inquiries:
Rachel Reiff
media@aratana.com
(913) 353-1050

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-report-first-quarter-2019-financial-results-300835211.html

SOURCE Aratana Therapeutics, Inc.

View Comments and Join the Discussion!